Role of tolvaptan in the management of hyponatremia in patients with lung and other cancers: current data and future perspectives

References

• AdroguéHJMadiasNEHyponatremiaN Engl J Med2000342211581158910824078
   PubMed Web of Science ®Google Scholar
• UpadhyayAJaberBLMadiasNEEpidemiology of hyponatremiaSemin Nephrol200929322723819523571
   PubMed Web of Science ®Google Scholar
• GillGHudaBBoydACharacteristics and mortality of severe hyponatraemia – a hospital-based studyClin Endocrinol (Oxf)200665224624916886968
   PubMed Web of Science ®Google Scholar
• SheaAMHammillBGCurtisLHSzczechLASchulmanKAMedical costs of abnormal serum sodium levelsJ Am Soc Nephrol200819476477018216314
   PubMed Web of Science ®Google Scholar
• WaikarSSMountDBCurhanGCMortality after hospitalization with mild, moderate, and severe hyponatremiaAm J Med2009122985786519699382
   PubMed Web of Science ®Google Scholar
• VerbalisJGBarsonyJSugimuraYHyponatremia-induced osteoporosisJ Bone Miner Res201025355456319751154
   PubMed Web of Science ®Google Scholar
• CastilloJJVincentMJusticeEDiagnosis and management of hyponatremia in cancer patientsOncologist201217675676522618570
   PubMed Web of Science ®Google Scholar
• DoshiSMShahPLeiXLahotiASalahudeenAKHyponatremia in hospitalized cancer patients and its impact on clinical outcomesAm J Kidney Dis201259222222822001181
   PubMed Web of Science ®Google Scholar
• PetereitCZabaOTeberILüdersHGrohéCA rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptanBMC Pulm Med2013135523987478
   PubMed Web of Science ®Google Scholar
• ListAFHainsworthJDDavisBWHandeKRGrecoFAJohnsonDHThe syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancerJ Clin Oncol198648119111983016206
   PubMed Web of Science ®Google Scholar
• GrohéCBerardiRBurstVHyponatraemia – SIADH in lung cancer diagnostic and treatment algorithmsCrit Rev Oncol Hematol20159611826070626
   PubMed Web of Science ®Google Scholar
• SawyerDBAnthracyclines and heart failureN Engl J Med2013368121154115623514294
   PubMed Web of Science ®Google Scholar
• BirkelandSAStormHHGlomerulonephritis and malignancy: a population-based analysisKidney Int200363271672112631139
   PubMed Web of Science ®Google Scholar
• IyerAVKrasnowSHDufourDRArcenasASSodium-wasting nephropathy caused by cisplatin in a patient with small-cell lung cancerClin Lung Cancer20035318718914667276
   PubMedGoogle Scholar
• PalmerBFHyponatraemia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wastingNephrol Dial Transplant200015226226810648680
   PubMed Web of Science ®Google Scholar
• HansenOSorensenPHansenKHThe occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year periodLung Cancer201068111111419535164
   PubMed Web of Science ®Google Scholar
• PetereitCZabaOTeberIGrohCIst die Hyponatriämie (HN) ein Prognosefaktor für das Gesamtüberleben der Patienten mit Lungenkarzinom? [Is hyponatremia a prognostic marker of survival for lung cancer?]Pneumologie201165956557121837588
   PubMedGoogle Scholar
• JacotWColinetBBertrandDQuality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patientsAnn Oncol20081981458146418356134
   PubMed Web of Science ®Google Scholar
• SenguptaABanerjeeSNBiswasNMThe incidence of hyponatraemia and its effect on the ECOG performance status among lung cancer patientsJ Clin Diagn Res2013781678168224086873
   PubMedGoogle Scholar
• GuytonACHallJETextbook of Medical Physiology10th edPhiladelphia (PA)W.B. Saunders2000
   Google Scholar
• BhattPRMcNeelyEBLinTEAdamsKFPattersonJHReview of tolvaptan’s pharmacokinetic and pharmacodynamic properties and drug interactionsJ Clin Med2014341276129026237603
   PubMedGoogle Scholar
• SorensenJBAndersenMKHansenHHSyndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant diseaseJ Intern Med19952382971107629492
   PubMed Web of Science ®Google Scholar
• LeeCRWatkinsMLPattersonJHVasopressin: a new target for the treatment of heart failureAm Heart J2003146191812851603
   PubMed Web of Science ®Google Scholar
• SchwartzWBBennettWCurelopSBartterFCA syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormoneAm J Med195723452954213469824
   PubMed Web of Science ®Google Scholar
• KleinLARabsonASWorksmanJIn vitro synthesis of vasopressin by lung tumor cellsSurg Forum1969202312335383060
   PubMedGoogle Scholar
• GeorgeJMCapenCCPhillipsASBiosynthesis of vasopressin in vitro and ultrastructure of a bronchogenic carcinoma. Patient with the syndrome of inappropriate secretion of antidiuretic hormoneJ Clin Invest19725111411485007044
   PubMed Web of Science ®Google Scholar
• ChuteJPTaylorEWilliamsJKayeFVenzonDJohnsonBEA metabolic study of patients with lung cancer and hyponatremia of malignancyClin Cancer Res2006123 Pt 188889616467103
   PubMed Web of Science ®Google Scholar
• GrossAJSteinbergSMReillyJGAtrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodiumCancer Res199353167748380126
   PubMed Web of Science ®Google Scholar
• HainsworthJDWorkmanRGrecoFAManagement of the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancerCancer19835111611656295592
   PubMed Web of Science ®Google Scholar
• PettengillOSFaulknerCSWurster-HillDHIsolation and characterization of a hormone-producing cell line from human small cell anaplastic carcinoma of the lungJ Natl Cancer Inst1977583511518190410
   PubMedGoogle Scholar
• BaylinSBWeisburgerWREgglestonJCVariable content of histaminase, L-dopa decarboxylase and calcitonin in small-cell carcinoma of the lung. Biologic and clinical implicationsN Engl J Med1978299310511026872
   PubMed Web of Science ®Google Scholar
• AyusJCVaronJArieffAIHyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runnersAnn Intern Med2000132971171410787364
   PubMed Web of Science ®Google Scholar
• PalmerBFGatesJRLaderMCauses and management of hyponatremiaAnn Pharmacother200337111694170214565794
   PubMed Web of Science ®Google Scholar
• AdroguéHJConsequences of inadequate management of hyponatremiaAm J Nephrol200525324024915914973
   PubMed Web of Science ®Google Scholar
• GennariFJCurrent concepts. Serum osmolality. Uses and limitationsN Engl J Med198431021021056361557
   PubMed Web of Science ®Google Scholar
• ChungHMKlugeRSchrierRWAndersonRJClinical assessment of extracellular fluid volume in hyponatremiaAm J Med19878359059083674097
   PubMed Web of Science ®Google Scholar
• HariprasadMKEisingerRPNadlerIMPadmanabhanCSNidusBDHyponatremia in psychogenic polydipsiaArch Intern Med198014012163916427458496
   PubMedGoogle Scholar
• MaliPMudugantiSRMujiburRMuraliNTolvaptan for SIADH in myelodysplastic syndrome with blast crisisWMJ20151142666826756059
   PubMedGoogle Scholar
• WatanabeKDohiKSugimotoTShort-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failureJ Cardiol201260646246923068288
   PubMed Web of Science ®Google Scholar
• PadfieldPLHodsmanGPMortonJJDemeclocycline in the treatment of the syndrome of inappropriate antidiuretic hormone release: with measurement of plasma ADHPostgrad Med J197854635623627103083
   PubMed Web of Science ®Google Scholar
• VerbalisJGEllisonHHobartMTolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT)Am J Kidney Dis201667689390126874645
   PubMed Web of Science ®Google Scholar
• SaitoTIshikawaSAbeKAcute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)J Clin Endocrinol Metab1997824105410579100572
   PubMed Web of Science ®Google Scholar
• ShoafSEBramerSLBricmontPZimmerCAPharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazideJ Cardiovasc Pharmacol200750221322217703139
   PubMed Web of Science ®Google Scholar
• SahayMSahayRHyponatremia: a practical approachIndian J Endocrinol Metab201418676077125364669
   PubMedGoogle Scholar
• PeriAGiulianiCManagement of euvolemic hyponatremia attributed to SIADH in the hospital settingMinerva Endocrinol2014391334124513602
   PubMed Web of Science ®Google Scholar
• BordiPTiseoMButiSRegolistiGArdizzoniAEfficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADHTumori20151012e51e5325702667
   PubMed Web of Science ®Google Scholar
• Samsca® [package insert]Rockville, MDOtsuka America Pharmaceutical, IncPrinceton, NJ2009
   Google Scholar
• TorresVEHigashiharaEDevuystOEffect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trialClin J Am Soc Nephrol201611580381126912543
   PubMed Web of Science ®Google Scholar
• KingJDRosnerMHOsmotic demyelination syndromeAm J Med Sci2010339656156720453633
   PubMed Web of Science ®Google Scholar
• ShoafSEBricmontPMallikaarjunSEffects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjectsBr J Clin Pharmacol201273457958721988334
   PubMed Web of Science ®Google Scholar
• SoodLSternsRHHixJKSilverSMChenLHypertonic saline and desmopressin: a simple strategy for safe correction of severe hyponatremiaAm J Kidney Dis201361457157823266328
   PubMed Web of Science ®Google Scholar
• VerbalisJGAdlerSSchrierRWEfficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretionEur J Endocrinol2011164572573221317283
   PubMed Web of Science ®Google Scholar
• BerlTQuittnat-PelletierFVerbalisJGOral tolvaptan is safe and effective in chronic hyponatremiaJ Am Soc Nephrol201021470571220185637
   PubMed Web of Science ®Google Scholar
• SalahudeenAKAliNGeorgeMLahotiAPallaSTolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safetyCancer2014120574475124895288
   PubMed Web of Science ®Google Scholar
• KenzSHaasCSWerthSCBohnetSBrabantGHigh sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH)Ann Oncol20112212269622021821
   PubMed Web of Science ®Google Scholar
• BerardiRCaramantiMFiordolivaIHyponatraemia is a predictor of clinical outcome for malignant pleural mesotheliomaSupport Care Cancer201523362162625142706
   PubMed Web of Science ®Google Scholar
• De Las PeasRPonceSHenaoFSIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptanSupport Care Cancer201624149950726431960
   PubMed Web of Science ®Google Scholar
• SchrierRWGrossPGheorghiadeMTolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremiaN Engl J Med2006355202099211217105757
   PubMed Web of Science ®Google Scholar